Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Moguisteine (BBR-2173) is a new-type peripheral non-narcotic antitussive drug.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | In stock | $ 30.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | Moguisteine (BBR-2173) is a new-type peripheral non-narcotic antitussive drug. |
In vitro | Moguisteine is a novel peripheral nonnarcotic antitussive agent that has proved to be as active as codeine in several experimental models of induced cough in guinea-pigs and dogs. It acts neither through the opiate receptors nor on the cough centre, and its action is possibly mediated by the interaction with rapidly adapting irritant receptors along the tracheobronchial tree. In controlled clinical trials, moguisteine has been shown to be safe and to effectively reduce cough associated with such respiratory disorders as acute upper respiratory tract infection, chronic bronchitis, pulmonary fibrosis and malignancies. |
Synonyms | BBR-2173 |
Molecular Weight | 339.41 |
Formula | C16H21NO5S |
CAS No. | 119637-67-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 63 mg/mL (185.6 mM)
Ethanol: 63 mg/mL (185.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Moguisteine 119637-67-1 Others Inhibitor BBR 2173 BBR-2173 inhibit BBR2173 inhibitor